Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel
Journal of Drugs in Dermatology · 2024
DOI: 10.36849/jdd.8246 ↗At a glance
Übersichtsarbeit in Journal of Drugs in Dermatology, 2024. Written by Joshua Burshtein and 11 co-authors. Major MEDLINE topics: Psoriasis, Consensus, Antibodies, Monoclonal, Humanized, Interleukin-17. Cited 2 times so far (Crossref).
Abstract (original language)
Intet abstract tilgængeligt.
Subjects
MeSH terms (MEDLINE)
Substances
Cite
APA
Burshtein, J., Shah, M., Zakria, D., Armstrong, A. W., Golant, A. K., Gottlieb, A. B., Weinberg, J. M., Kircik, L., Han, G., Langley, R. G., Neimann, A. L., & Lebwohl, M. (2024). Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.8246
Vancouver
Burshtein J, Shah M, Zakria D, Armstrong AW, Golant AK, Gottlieb AB, et al. Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel. Journal of Drugs in Dermatology. 2024. doi:10.36849/jdd.8246
BibTeX
@article{Burshtein2024,
author = {Burshtein, Joshua and Shah, Milaan and Zakria, Danny and Armstrong, April W and Golant, Alexandra K and Gottlieb, Alice B and Weinberg, Jeffrey M and Kircik, Leon and Han, George and Langley, Richard G and Neimann, Andrea L and Lebwohl, Mark},
title = {Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel},
journal = {Journal of Drugs in Dermatology},
year = {2024},
doi = {10.36849/jdd.8246}
}
EUVIMED